Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESGO 2021 | Immune checkpoint inhibitors in ovarian cancer

Eric Pujade-Lauraine • 24 Oct 2021
ESGO 2021
Gynecological Cancer Ovarian Cancer

Eric Pujade-Lauraine, MD, PhD, Hôpital Hôtel-Dieu, Paris, France, outlines the use of immunotherapy in ovarian cancer, the PD1/PD-L1 pathway, as well as novel targets for therapy. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.

More from Eric Pujade-Lauraine

3:37
Selecting patients to be treated with maintenance olaparib in the PAOLA-1 trial
Eric Pujade-Lauraine • 20 Feb 2023
3:06
Results from the JAVELIN Ovarian 200 biomarker analysis
Eric Pujade-Lauraine • 24 Oct 2021
1:06
Improving immunotherapy outcomes in ovarian cancer
Eric Pujade-Lauraine • 24 Oct 2021
2:50
AURELIA: Phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancer
Eric Pujade-Lauraine • 26 Sep 2015

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals